Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 7/20 | 0.54 |
| ▸ | BCL3 | P20749 | 5/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1322479 | 0.93 | SMYD2 (0.51) | SMYD2BCL3KDM4EALDH1A1HPGD | |
| SCHEMBL1323995 | 0.92 | SMYD2 (0.50) | SMYD2BCL3KDM4EALDH1A1HPGD | |
| SCHEMBL1322559 | 0.92 | SMYD2 (0.54) | SMYD2BCL3KDM5BKDM4EALDH1A1 | |
| SCHEMBL1323990 | 0.90 | SMYD2 (0.57) | SMYD2KDM5BKDM4EALDH1A1HPGD | |
| SCHEMBL12118856 | 0.90 | EPHX2 (0.49) | SMYD2BCL3KDM4EALDH1A1HPGD | |
| SCHEMBL1322467 | 0.90 | ALDH1A1 (0.55) | SMYD2BCL3KDM5BKDM4EALDH1A1 | |
| SCHEMBL1322925 | 0.89 | SMYD2 (0.49) | SMYD2BCL3KDM5BKDM4EALDH1A1 | |
| SCHEMBL16456633 | 0.88 | AURKA (0.42) | SMYD2BCL3KDM5BALDH1A1KDR | |
| Trifluoroacetic Acid SCHEMBL1322541 | 0.88 | EPHX2 (0.47) | SMYD2BCL3KDM5BKDM4EALDH1A1 | |
| SCHEMBL1323513 | 0.87 | EPHX2 (0.53) | SMYD2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058290-B2 | E.g., 1-[4-(3-amino-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]-3-(2-fluoro-5-trifluoromethylphenyl)urea; and N-(6-{4-[3-(2-fluoro-5-trifluoromethylphenyl)ureido]-phenyl}-1H-pyrazolo[3,4-b]pyridin-3-yl))thiophene-3-carboxamide; kinase inhibitors, anticancer agents | AVENTIS PHARMA S.A. (FR) | 2011-11-15 | — | — | US | claimed |
| US-8058290-B2 | E.g., 1-[4-(3-amino-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]-3-(2-fluoro-5-trifluoromethylphenyl)urea; and N-(6-{4-[3-(2-fluoro-5-trifluoromethylphenyl)ureido]-phenyl}-1H-pyrazolo[3,4-b]pyridin-3-yl))thiophene-3-carboxamide; kinase inhibitors, anticancer agents | AVENTIS PHARMA S.A. (FR) | 2011-11-15 | — | — | US | disclosed |
| US-8058290-B2 | E.g., 1-[4-(3-amino-1H-pyrazolo[3,4-b]pyridin-6-yl)phenyl]-3-(2-fluoro-5-trifluoromethylphenyl)urea; and N-(6-{4-[3-(2-fluoro-5-trifluoromethylphenyl)ureido]-phenyl}-1H-pyrazolo[3,4-b]pyridin-3-yl))thiophene-3-carboxamide; kinase inhibitors, anticancer agents | AVENTIS PHARMA S.A. (FR) | 2011-11-15 | — | — | US | disclosed |
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-31 | — | — | US | disclosed |
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-31 | — | — | US | disclosed |
| WO-2007017577-A1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | PRMT7, PRKACA, PRKX | SMYD2 1158/4885BCL3 642/4885KDM5B 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.